Literature DB >> 29713055

A kinome-wide high-content siRNA screen identifies MEK5-ERK5 signaling as critical for breast cancer cell EMT and metastasis.

Simona Pavan1, Nathalie Meyer-Schaller2, Maren Diepenbruck2, Ravi Kiran Reddy Kalathur2, Meera Saxena2, Gerhard Christofori3.   

Abstract

An epithelial to mesenchymal transition (EMT) has been correlated to malignant tumor progression and metastasis by promoting cancer cell migration and invasion and chemoresistance. Hence, finding druggable EMT effectors is critical to efficiently interfere with metastasis formation and to overcome therapy resistance. We have employed a high-content microscopy screen in combination with a kinome and phosphatome-wide siRNA library to identify signaling pathways underlying an EMT of murine mammary epithelial cells and breast cancer cells. This screen identified the MEK5-ERK5 axis as a critical player in TGFβ-mediated EMT. Suppression of MEK5-ERK5 signaling completely prevented the morphological and molecular changes occurring during a TGFβ-induced EMT and, conversely, forced highly metastatic breast cancer cells into a differentiated epithelial state. Inhibition of MEK5-ERK5 signaling also repressed breast cancer cell migration and invasion and substantially reduced lung metastasis without affecting primary tumor growth. The results suggest that the MEK5-ERK5 signaling axis via activation of MEF2B and other transcription factors plays an important role in the induction and maintenance of breast cancer cell migration and invasion and thus represents an exploitable target for the pharmacological inhibition of cancer cell metastasis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29713055     DOI: 10.1038/s41388-018-0270-8

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  66 in total

1.  PB1 domains of MEKK2 and MEKK3 interact with the MEK5 PB1 domain for activation of the ERK5 pathway.

Authors:  Kazuhiro Nakamura; Gary L Johnson
Journal:  J Biol Chem       Date:  2003-08-11       Impact factor: 5.157

Review 2.  MAP kinases and the control of nuclear events.

Authors:  A G Turjanski; J P Vaqué; J S Gutkind
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

3.  The PRK2 kinase is a potential effector target of both Rho and Rac GTPases and regulates actin cytoskeletal organization.

Authors:  S Vincent; J Settleman
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

Review 4.  Regulating Rho GTPases and their regulators.

Authors:  Richard G Hodge; Anne J Ridley
Journal:  Nat Rev Mol Cell Biol       Date:  2016-06-15       Impact factor: 94.444

Review 5.  TGF-beta signaling in cancer--a double-edged sword.

Authors:  R J Akhurst; R Derynck
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

6.  Proangiogenic factor PlGF programs CD11b(+) myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors.

Authors:  Julien Laurent; Eveline Faes-van't Hull; Cedric Touvrey; François Kuonen; Qiang Lan; Girieca Lorusso; Marie-Agnès Doucey; Laura Ciarloni; Natsuko Imaizumi; Gian Carlo Alghisi; Ernesta Fagiani; Khalil Zaman; Roger Stupp; Masabumi Shibuya; Jean-François Delaloye; Gerhard Christofori; Curzio Ruegg
Journal:  Cancer Res       Date:  2011-04-20       Impact factor: 12.701

Review 7.  Role of mitogen-activated protein kinase kinase 4 in cancer.

Authors:  A J Whitmarsh; R J Davis
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

Review 8.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

9.  Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.

Authors:  Xiaofeng Zheng; Julienne L Carstens; Jiha Kim; Matthew Scheible; Judith Kaye; Hikaru Sugimoto; Chia-Chin Wu; Valerie S LeBleu; Raghu Kalluri
Journal:  Nature       Date:  2015-11-11       Impact factor: 49.962

10.  Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.

Authors:  Kari R Fischer; Anna Durrans; Sharrell Lee; Jianting Sheng; Fuhai Li; Stephen T C Wong; Hyejin Choi; Tina El Rayes; Seongho Ryu; Juliane Troeger; Robert F Schwabe; Linda T Vahdat; Nasser K Altorki; Vivek Mittal; Dingcheng Gao
Journal:  Nature       Date:  2015-11-11       Impact factor: 49.962

View more
  17 in total

Review 1.  siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion.

Authors:  Worapol Ngamcherdtrakul; Wassana Yantasee
Journal:  Transl Res       Date:  2019-08-19       Impact factor: 7.012

2.  A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.

Authors:  Kazem Nouri; Taha Azad; Elizabeth Lightbody; Prem Khanal; Christopher J Nicol; Xiaolong Yang
Journal:  FASEB J       Date:  2019-08-20       Impact factor: 5.191

3.  BAY-885, a mitogen-activated protein kinase kinase 5 inhibitor, induces apoptosis by regulating the endoplasmic reticulum stress/Mcl-1/Bim pathway in breast cancer cells.

Authors:  Lei Wang; Xiaochun Ji; Chenxiao Mao; Rui Yu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

4.  Expression of TRPC1 and SBEM protein in breast cancer tissue and its relationship with clinicopathological features and prognosis of patients.

Authors:  Yongqing Zhang; Xiaoqin Lun; Weiling Guo
Journal:  Oncol Lett       Date:  2020-10-29       Impact factor: 2.967

5.  The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion.

Authors:  Qiuping Xu; Jingwei Zhang; Brian A Telfer; Hao Zhang; Nisha Ali; Fuhui Chen; Blanca Risa; Adam J Pearson; Wei Zhang; Katherine G Finegan; Ahmet Ucar; Emanuele Giurisato; Cathy Tournier
Journal:  Oncogene       Date:  2021-05-12       Impact factor: 9.867

6.  Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapy.

Authors:  Caroline K Søgaard; Anala Nepal; Voin Petrovic; Animesh Sharma; Nina-Beate Liabakk; Tonje S Steigedal; Marit Otterlei
Journal:  Oncotarget       Date:  2019-12-31

7.  Targeting MEK5 impairs nonhomologous end-joining repair and sensitizes prostate cancer to DNA damaging agents.

Authors:  Constantinos G Broustas; Axel J Duval; Kunal R Chaudhary; Richard A Friedman; Renu K Virk; Howard B Lieberman
Journal:  Oncogene       Date:  2020-01-24       Impact factor: 9.867

Review 8.  Differential Co-Expression Analyses Allow the Identification of Critical Signalling Pathways Altered during Tumour Transformation and Progression.

Authors:  Aurora Savino; Paolo Provero; Valeria Poli
Journal:  Int J Mol Sci       Date:  2020-12-12       Impact factor: 5.923

9.  Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer.

Authors:  Jinyang Wang; Yuan Zhang; Yi Xiao; Xiangliang Yuan; Ping Li; Xiao Wang; Yimin Duan; Victoria L Seewaldt; Dihua Yu
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

10.  SUMOylation Is Required for ERK5 Nuclear Translocation and ERK5-Mediated Cancer Cell Proliferation.

Authors:  Tatiana Erazo; Sergio Espinosa-Gil; Nora Diéguez-Martínez; Néstor Gómez; Jose M Lizcano
Journal:  Int J Mol Sci       Date:  2020-03-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.